NCT05839236 is a Phase 1 clinical trial of Atorvastatin Calcium Tablets in COVID-19 Stress Syndrome, sponsored by Yang I. Pachankis.

Who is sponsoring NCT05839236?

NCT05839236 is sponsored by Yang I. Pachankis.

What drugs are being tested in NCT05839236?

Interventions in NCT05839236: Atorvastatin Calcium Tablets.

What condition does NCT05839236 study?

NCT05839236 studies COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism, COVID-19 Post-Intensive Care Syndrome, COVID-19-Associated Stroke, COVID-19 Respiratory Infection.

Is NCT05839236 still recruiting?

NCT05839236 is currently status unknown. Last updated 6 May 2023.

Last reviewed 2023-05-06 · How we verify

NCT05839236

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Vaccination Detoxification in LDL-C

Status unknown Phase 1 Last updated 6 May 2023

What this trial tests

Phase 1 trial testing Atorvastatin Calcium Tablets in COVID-19 Stress Syndrome in 1 participant. Status unknown.

Timeline

1 May 2023

Primary endpoint
30 June 2023

31 July 2023

Quick facts

Lead sponsor	Yang I. Pachankis
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	1
Start date	1 May 2023
Primary completion	30 June 2023
Estimated completion	31 July 2023
Sites	1 location across China

Drugs / interventions tested

Atorvastatin Calcium Tablets — full drug profile →

Conditions studied

COVID-19 Stress Syndrome — all drugs for COVID-19 Stress Syndrome →
COVID-19 Vaccine Adverse Reaction — all drugs for COVID-19 Vaccine Adverse Reaction →
COVID-19-Associated Thromboembolism — all drugs for COVID-19-Associated Thromboembolism →
COVID-19 Post-Intensive Care Syndrome — all drugs for COVID-19 Post-Intensive Care Syndrome →

Sponsor

Yang I. Pachankis — full company profile →

Who can join

Adults 18 to 65, male only, with COVID-19 Stress Syndrome or COVID-19 Vaccine Adverse Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study hypothesizes that SARS-CoV-2 vaccination poisoning hibernates in human host in Low Density Lipoprotein Cholesterol (LDL-C). The clinical trial is a follow-up from the intervention trial with NCT number NCT05711810. It tests the use of Atorvastatin Calcium Tablets for detoxification and prevention of blood acidification, and the use of the Chinese herb compounded Anti-Viral Granules for the detoxification in the endocrine system.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Black Box warning: Exploring the ethical considerations and mitigating medicolegal risk in prescribing antidepressants to young adults
Thiagayson P. · · 2025
Neuropathic Pains in the Age of Post-COVID-19-Vaccination
Cao Y. · · 2025
Recruiting hard-to-reach populations for surveys: A case of people with schizophrenia and coexisting diabetes
Rønne S, Cleal B, Gæde P, Arnfred S, et al · · 2025

Verify or expand the search:

Other trials of Atorvastatin Calcium Tablets

Trials testing the same drug.

NCT07378228 — Weak Pulse at Yang and Wiry Pulse at Yin Theory · NA · completed
NCT05641753 — Cholesterol Lowering and Residual Risk in Diabetes, Type 1 · Phase 4 · recruiting
NCT05238012 — Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes · Phase 4 · completed

Other recruiting trials for COVID-19 Stress Syndrome

Currently open trials in the same condition.

NCT05459896 — A Health Apps for Post-Pandemic Years for People With Physiological and Psychosocial Distress · NA · recruiting

Other Yang I. Pachankis trials

Trials by the same sponsor.

NCT05711810 — Medicine-induced Cardiac Hemodialysis on COVID-19 · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05839236 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yang I. Pachankis
Last refreshed: 6 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05839236.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing